Kornimate/medical-research-clean huggingface dataset:
heart biomarker evaluation in apnea treatment

Conditions: Cardiovascular Disease; Obstructive Sleep Apnea; Coronary Artery Disease

Summary: this study examines the role of sleep apnea treatment in improving cardiovascular biomarkers.

this is a phase ii randomized controlled trial that will evaluate the effects of supplemental nocturnal oxygen or positive airway pressure (pap) therapy, compared to optimal medical preventive therapy for cardiovascular disease (cvd) risk, on biomarkers of cvd risk in obstructive sleep apnea (osa) patients at high risk for cvd events. the study will focus on patients with moderate to severe osa but only mild osa symptoms. eligible participants have a history or symptoms of heart disease and have symptoms of sleep apnea or snoring. participants will be contributing to medical knowledge about different options that can be used to improve heart disease in people with sleep apnea.

Eligibility criteria:
inclusion criteria: * established coronary artery disease or established cardiovascular disease risk factors * home sleep test that showed moderately severe sleep apnea exclusion criteria: * poorly controlled health * currently using supplemental oxygen or pap for osa
learning retention in radiograph interpretation

Conditions: Fractures, Bone

Summary: learning retention after the deliberate practice of radiograph interpretation may be challenging for image types which are common enough to be clinically relevant but not so common that proficiency can be sustained through clinical practice. this is especially relevant for radiographs such as paediatric elbow films (exr) that carry high risks for the patient if pathology is missed. building on prior research in this area, this study will develop an innovative computer learning application for paediatric exr interpretation. after an initial learning period, this study will quantitatively determine the rate of skill decay and the optimal timing for refresher-education.

objectives learning retention after the deliberate practice of radiograph interpretation may be challenging for image types which are common enough to be clinically relevant but not so common that proficiency can be sustained through clinical practice. this is especially relevant for radiographs such as paediatric elbow films (exr) that carry high risks for the patient if pathology is missed. building on our prior research in this area, this study will develop an innovative computer learning application for paediatric exr interpretation. after an initial learning period, this study will quantitatively determine the rate of skill decay and the optimal timing for refresher-education. design a prospective cohort design with purposive sampling will be used to develop the exr education intervention. a four arm randomized control trial will be used to test for the outcomes of skill decay and optimal timing of refresher education. setting the education intervention will be developed at two tertiary care children's hospitals. study participants will include physicians from two large paediatric education networks in the united states (paediatric outcomes in simulation education) and canada (paediatric emergency research canada). statistical analysis for the primary analysis, a four-group multi-level model with time-points nested within participants will be used. secondary analyses will include a time series approach within each block of 20 test exr to check for sequential effects, and between each block to determine whether we can efficiently model skill decay curves that can separate the underlying learning attrition curve from the effects of "boluses" of education. conclusion this study anticipates that learners will increase their learning of elbow radiographs by participating in the deliberate practice of radiographs, with skill decay over time that will be mitigated by refresher education. the results will allow evidence based recommendations regarding refresher education for learning from item banks of radiographs.

Eligibility criteria:
inclusion criteria: * pediatric and emergency medicine residents enrolled in an accredited residency in canada and the united states exclusion criteria: * none

Keywords: education (medical); retention;
efficacy of lyophilized dried cornus mas l. on anthropometric and biochemical parameters in insulin resistance

Conditions: Insulin Resistance; Obesity; PreDiabetes

Summary: the aim of this study is to determine the effect of 3 months supplementation of lyophilize dried cornelian cherry (cornus mas l.) on women diagnosed with insulin resistance. the baseline and end biochemical parameters and anthropometric measurements will be compared with control subjects.

the main purpose of this study is to determine the efficacy of the lyophilizer-dried powder form of cornelian cherry (cornus mas l.) grown in our country on inflammation in women with insulin resistance by biochemical parameters. sub-objectives of the study; * determining the presence of inflammation in women with insulin resistance. * determination of the effect of cornelian cherry on both fasting blood glucose, insulin and blood lipid profile. * determination of both anti-inflammatory, antidiabetic and antioxidant effects of cornelian cherry. * determination of the effect of cornelian cherry on anthropometric measurements. the aim of this study is to compare the anthropometric measurements and biomarkers of women with insulin resistance as a result of the consumption of powdered cornelian cherry (cornus mas l.) that has been freeze-dried at -55 degrees with a lyophilizer device for 12 weeks.

Eligibility criteria:
inclusion criteria: * women aged between 18 and 45 years with insulin resistance. * those who have not experienced menopause * those who applied to the obesity clinic * volunteers * those who signed the consent form exclusion criteria: * those who use medicine for diabetes and thyroid diseases, * those taking hormone therapy * pregnant and lactating women * those with a history of cancer * patients with communication problems.

Keywords: cornelian cherry cornus mas l. insulin resistance nutrition anthropometry
the loop observational study

Conditions: Diabetes Mellitus, Type 1

Summary: an observational study to collect data on the efficacy, safety, usability, and quality of life/psychosocial effects of the loop diy automated insulin delivery system.

the study will include both adults and youth in the united states, with a recruitment goal of at least 300-1,250 participants. data to be collected to address the study objective will include cgm metrics; hba1c; insulin delivery data; carbohydrate data; activity data from healthkit; self-reported adverse events (e.g., severe hypoglycemia, diabetic ketoacidosis, hospitalizations); self-reported device issues; and psychosocial and user experience/treatment satisfaction surveys. online forms will allow participants to report weekly device issues and serious adverse events including severe hypoglycemia, diabetic ketoacidosis, and hospitalizations. general data updates will be obtained after three, six, and 12 months (and every six months thereafter if study participation continues). a fingerstick blood sample will be collected for hba1c measurement after three months for cohort a and after six and 12 months for both cohorts. quality-of-life/psychosocial and treatment satisfaction questionnaires will be completed after six and 12 months; new users also will complete questionnaires after 3 months. virtual focus groups will be completed within the first three months of starting loop and at 12 months.

Eligibility criteria:
inclusion criteria: * type 1 diabetes * currently have, or have ordered, the hardware devices necessary to use loop * currently use loop or have plans to start using loop for insulin delivery * willing and able to provide informed consent (or be a parent or other legally authorized representative) and to provide the data and complete questionnaires that are part of the protocol * resident of u.s. exclusion criteria: * none

Keywords: loop rileylink type 1 diabetes
effectiveness of ivermectin and doxycycline on covid-19 patients

Conditions: Covid19

Summary: a randomized controlled trial on using ivermectin and doxycycline to treat mild-moderate outpatients, severe, and critical inpatients of coronavirus disease 19 (covid-19) along with standard of care. seventy iraqi covid-19 patients received ivermectin and doxycycline plus standard of care versus seventy iraqi covid-19 patients received standard of care only. .

objectives: covid-19 patients suffer from the lack of curative therapy. hence, there is an urgent need to try old re-purposed drugs on covid-19. methods: randomized controlled study on 70 covid-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg po of ivermectin per day for 2 days along with 100mg po doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 covid-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. the time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters.

Eligibility criteria:
inclusion criteria: * covid-19 patients at any stage of this disease exclusion criteria: * patients of allergic history to ivermectin or to doxycyline

Keywords: ivermectin doxycycline covid-19 coronavirus sars-cov-2
a study of scg101 tcr-t cell therpay in the treatment of subjects with hepatitis b virus-related

Conditions: HCC; Hepatitis B Virus Related Hepatocellular Carcinoma; Hepatocellular Carcinoma

Summary: this is a phase i clinical study aimed to assess the safety, tolerability, and efficacy of scg101 monotherapy for patients with hbv-hcc.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed hepatocellular carcinoma (hcc) * subjects with hcc who have received standard systemic therapies * hla-a \*02 * bclc stage b or c * child-pugh score ≤ 7 ol * serum hbeag negative, serum (or tumor tissue) hbsag positive, and serum hbv-dna must be ≤ 1 × 1000 iu/ml * have at least one measurable leasion at baseline as per mrecist and irecist * life expectancy of 3 months or greater * the organ function is in good condition. exclusion criteria: * subjects with history of another primary cancer within 5 years * central nervous system metastasis and clinically significant central nervous system disease * previous or current coexistence of hepatic encephalopathy * currently present with symptomatic third space fluid accumulation * hypertension that is poorly controlled, as determined by researchers (i.e., arterial hypertension that remains uncontrolled despite standard treatment) * known history of neurological or mental disorder, including epilepsy or dementia * suffering from active autoimmune diseases, or other significant ongoing immune rejection based on pathology and clinical diagnosis * prior exposure to any cell therapy such as, but not limited to killer (nk) cells, cytokine-induced killer (cik) cells, dendritic cells (dc), cytotoxic t lymphocytes (ctl), stem cell therapy * positive for hcv - rna test or positive for hav igm antibody or positive for hdv igm antibody; or there is current evidence indicating the presence of hev infection * allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine) * any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation
growth hormone resistance of beta-cells in women and people

Conditions: Healthy; Obesity

Summary: the purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the university of missouri. our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes and type 2 diabetes.


Eligibility criteria:
inclusion criteria: * 18 to 45 years old * hemoglobin hba1c ≤5.6% and fasting blood glucose \<100 mg/dl * body mass index ≥30.0 kg/m2 and \<45.0 kg/m2 additional, group-specific inclusion criteria: * family history of type 2 diabetes: first degree relative with type 2 diabetes * control group: no family history of type 2 diabetes exclusion criteria: * pregnant, planning to become pregnant during the study, or breastfeeding * current diagnosis or history of type 1 or type 2 diabetes * use of medications that can impact the study outcomes (e.g., glp-1 receptor agonists) * history of bariatric surgery * known hypothyroidism or use of thyroid medications * history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as turner syndrome, prader-willi syndrome, or renal impairment * current cancer or cancer that has been in remission less than 5 years * first degree relative with type 1 diabetes diagnosis * evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease) * alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day * greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration * mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent
usefulness of myocardial deformation imaging for trastuzumab-induced cardiotoxicity

Conditions: Left Ventricular Function Systolic Dysfunction; Cardiotoxicity

Summary: trastuzumab prolongs survival in patients with human epidermal growth factor receptor type 2-positive breast cancer. sequential left ventricular (lv) ejection fraction (ef) assessment has been mandated to detect myocardial dysfunction because of the risk of heart failure with this treatment. myocardial deformation imaging is a sensitive means of detecting lv dysfunction, but this technique has not been evaluated in patients treated with trastuzumab. the aim of this study was to investigate whether changes in tissue deformation, assessed by myocardial strain and strain rate (sr), are able to identify lv dysfunction earlier than conventional echocardiographic measures in patients treated with trastuzumab.

the investigators will prospectively evaluate whether changes in tissue deformation, assessed by myocardial strain and strain rate (sr) and identify possibility of early detection of lv dysfunction in patients treated with trastuzumab.

Eligibility criteria:
inclusion criteria: * her2(+) breast cancer, anticipating trastuzumab therapy exclusion criteria: * refusal to informed consent * congenital heart disease * significant arrhythmia in ekg * regional wall motion abnormality (+) in echocardiography * poor sonic window

Keywords: myocardial deformation imaging trastuzumab
circulating micrornas as disease markers in pediatric cancers

Conditions: Leukemia; Lymphoma; Central Nervous System

Summary: micrornas are small molecules which have recently been discovered in cells. they are known to be responsible for the normal development of cells and when they are disrupted can contribute to the development of cancer. many previous studies have been done evaluating the expression of micrornas in normal tissues as well as a wide variety of cancers. recently, micrornas from tumor cells have been detected circulating in the blood of patients with cancer. this presents a novel opportunity to use micrornas in the blood as an early predictor of cancer as well as a marker of response to therapy. no previous studies have been performed evaluating micrornas in the blood or cerebrospinal fluid of patients with childhood cancers. we propose a feasibility study to evaluate the presence of micrornas in the blood and cerebrospinal fluid of patients with central nervous system tumors, leukemia and lymphoma who are currently on chemotherapy and undergoing blood draws, lumbar punctures and/or reservoir taps for routine clinical care. if we're able to identify circulating micrornas in this population of pediatric patients, we will build upon this data in proposing a future study.


Eligibility criteria:
inclusion criteria: * all children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors * age: greater than 3 years and less than or equal to 21 years of age * patients must be in a phase of their treatment during which routine blood draws, lumbar punctures or csf sampling from ommaya reservoirs are required for treatment of their cancers. exclusion criteria: * patients who have completed treatment and do not require routine blood draws and/or lumbar punctures * patients who are considered too ill to participate as determined by their treating physician * patients with a known genetic condition that predisposed them to the development of cancer.
effects of progressive muscle relaxation and mindfulness meditation in patients with chronic obstructive pulmonary disease

Conditions: COPD; Mediation; Fatigue; Symptoms and Signs

Summary: patients with copd will be entered. participants will be randomized to one of three study arms: arm 1: meditation; arm 2: relaxation; arm 3: control. hypothesis: progressive muscle relaxation and mindfulness meditation will decrease severity of dyspnea, fatigue and care dependency.

previous reports have revealed that progressive muscle relaxation and meditation are decreasing symptoms burden in chronic disease. on the other hand, no study has been conducted to determine the effects of progressive relaxation exercise and mindfulness meditation on dyspnea, fatigue and care dependency in patients with copd. the present study investigates the effects of progressive muscle relaxation and mindfulness meditation in a single-site, 3-arm, assessor-blinded randomized, controlled study of 65 copd patients. arm 1: meditation; arm 2: relaxation; arm 3: control.the investigators hypothesize that progressive muscle relaxation and mindfulness meditation will decrease the severity of dyspnea, fatigue and care dependency.

Eligibility criteria:
inclusion criteria: * older than 40 years * diagnosed with stage iii-iv copd * had at least primary school degree * had no cognitive dysfunction, or communication problems * were residing in ankara. exclusion criteria: * history of cognitive dysfunction, or communication problems * illiteracy * applying any complementary and integrative approach during the study * participating in a pulmonary rehabilitation program during the study.
evaluation of manufacturing lot of staphvax

Conditions: Staphylococcal Infections; Chronic Kidney Failure

Summary: this study answers a u.s. food and drug administration requirement for evaluation in people of a manufacturing lot of vaccine. subjects receive one dose of one lot of vaccine. the antibodies in the blood measure the immunogenicity of the vaccine, and typical vaccine safety information is also collected.


Eligibility criteria:
inclusion criteria: * 8 wk of hemodialysis for esrd, * have written informed consent, * a negative serum pregnancy test if appropriate, * and expect to comply with protocol procedures and schedule exclusion criteria: * known hiv, * immunomodulatory drugs, * malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early stage prostate cancer), * active infection in the 2 weeks prior to study injection, * serious s. aureus infection within the last 3 months prior to injection, * use of investigational drugs, vaccines or devices within the prior 30 days, * hypersensitivity to components of staphvax
effectiveness of a digital treatment for adolescents with chronic pain

Conditions: Chronic Pain

Summary: research has shown that the prevalence of chronic pain in adolescents is high and increasing. these young people report significant changes in both their physical and psychological functioning. currently, psychosocial treatments enjoy strong empirical support and are crucial to maintaining and improving the quality of life of adolescents suffering from chronic pain. however, the availability of these evidence-based interventions is insufficient to meet the high demand, especially outside of large cities. the aim of this project is to develop a digital treatment that helps improve the quality of life of adolescents with chronic pain and complementary websites for their parents and teachers.


Eligibility criteria:
inclusion criteria: * 12-18 years old, * having a non-oncology secondary chronic pain problem, * having internet access, * a parent willing to participate in the study, * providing informed consent/assent. exclusion criteria: * cognitive or language problems

Keywords: chronic pain mhealth adolescent mobile application
prevalence of perimyocarditis after covid-19 vaccine

Conditions: Perimyocarditis; Covid19

Summary: the aim of this study is to determine whether there is a higher prevalence of perimyocarditis after undergoing vaccination for covid-19.


Eligibility criteria:
inclusion criteria: * patients planning pfizer-biontech bnt162b2 vaccination against covid19 exclusion criteria: * patients infected with covid19
the effect of the covid-19 pandemic on frailty in liver transplant candidates

Conditions: Frailty; Sarcopenia; COVID-19

Summary: frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures \[1\]. sarcopenia is degenerative loss of skeletal muscle mass and strength. it is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.

this study seeks to examine whether the sars-cov-2 (covid-19) pandemic, an ongoing global health crisis that was declared a national emergency by the us federal government on march 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.

Eligibility criteria:
inclusion criteria: * age 18 years and older underwent pre-transplant frailty assessment (pfa) at mdmc exclusion criteria: * not a patient at liver institute at methodist dallas